Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

clear all | select all

Conference Years:

clear all | select all

Days Within Meeting:

clear all | select all

Conferences:

Availability:

clear all | select all

Participation Type:

clear all | select all

Topic Tracks*:

clear all | select all

Organ Site Tracks*:

  • Sort by:
  • Browse by:
<< first | < prev page: of 40 records per page: next > | last >>
pages: 1 2 3 4 5 ... 37 38 39 40 presentations: 1 to 25 of 990
Predictive Biomarkers for Immunotherapy
  •  
  • Permission not
    granted for presentation
  •  
  •  
Biomarkers of systemic inflammation associated to reduced clinical activity of atezolizumab monotherapy in patients with metastatic triple negative breast cancer
Luciana Molinero
Genentech, South San Francisco, CA, United States
from AACR Annual Meeting 2019 on March 31, 2019 12:45 PM-3:00 PM
Predictive Biomarkers for Immunotherapy
  •  
  • Permission not
    granted for presentation
  •  
  •  
A strong HPV-specific T-cell response after chemo-immunotherapy for advanced cervical cancer is associated with prolonged survival
Cornelis J M Melief
Leiden Univ. Medical Ctr. & ISA Pharmaceuticals BV, Leiden, Netherlands
from AACR Annual Meeting 2019 on March 31, 2019 12:45 PM-3:00 PM
Predictive Biomarkers for Immunotherapy
  •  
  • Permission not
    granted for presentation
  •  
  •  
Analysis of immune cell infiltrates as predictors of response to the checkpoint inhibitor pembrolizumab in the neoadjuvant I-SPY 2 TRIAL
Michael J Campbell
UCSF, San Francisco, CA, United States
from AACR Annual Meeting 2019 on March 31, 2019 12:45 PM-3:00 PM
Predictive Biomarkers for Immunotherapy
A Phase Ib study of CD40 agonistic monoclonal antibody APX005M together with gemcitabine (Gem) and nab-paclitaxel (NP) with or without nivolumab (Nivo) in untreated metastatic ductal pancreatic adenocarcinoma (PDAC) patients
Mark H O'Hara
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, United States
from AACR Annual Meeting 2019 on March 31, 2019 12:45 PM-3:00 PM
Predictive Biomarkers for Immunotherapy
Discussant
Aung Naing
UT MD Anderson Cancer Ctr., Houston, TX, United States
from AACR Annual Meeting 2019 on March 31, 2019 12:45 PM-3:00 PM
Can the Challenge of NSCLC Resistance Be MET or Will We Not MEK It?
  •  
  • Permission not
    granted for presentation
  •  
  •  
Preliminary efficacy and safety results of savolitinib treating patients with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations
Shun Lu
Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China
from AACR Annual Meeting 2019 on March 31, 2019 3:00 PM-5:00 PM
Can the Challenge of NSCLC Resistance Be MET or Will We Not MEK It?
TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-amplified NSCLC after progression on prior epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)
Lecia Sequist
Massachusetts General Hospital, Boston, MA, United States
from AACR Annual Meeting 2019 on March 31, 2019 3:00 PM-5:00 PM
Can the Challenge of NSCLC Resistance Be MET or Will We Not MEK It?
Osimertinib plus selumetinib for patients (pts) with EGFR-mutant (EGFRm) NSCLC following disease progression on an EGFR-TKI: Results from the Phase Ib TATTON study
Suresh S Ramalingam
Emory Univ. Winship Cancer Inst., Atlanta, GA, United States
from AACR Annual Meeting 2019 on March 31, 2019 3:00 PM-5:00 PM
Can the Challenge of NSCLC Resistance Be MET or Will We Not MEK It?
Discussant
Roy S Herbst
Yale Cancer Ctr., New Haven, CT, United States
from AACR Annual Meeting 2019 on March 31, 2019 3:00 PM-5:00 PM
Presidential Address
Turning the heat up on pancreatic cancer: Lessons on overcoming a “cold” immunologic microenvironment
Elizabeth M Jaffee
Johns Hopkins Sidney Kimmel Comp. Cancer Ctr., Baltimore, MD, United States
from AACR Annual Meeting 2019 on March 31, 2019 5:30 PM-6:15 PM
Optimizing PD-1/PD-L1 Immune Checkpoint Inhibitor Therapy: Dedicated to the Memory of Waun Ki Hong
Introduction
Nilofer S Azad
Johns Hopkins Sidney Kimmel Comp. Cancer Ctr., Baltimore, MD, United States
from AACR Annual Meeting 2019 on April 1, 2019 10:30 AM-12:45 PM
Optimizing PD-1/PD-L1 Immune Checkpoint Inhibitor Therapy: Dedicated to the Memory of Waun Ki Hong
Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with melanoma previously treated with anti-PD1 therapy
Ryan J. Sullivan
Massachusetts General Hospital, Boston, MA, United States
from AACR Annual Meeting 2019 on April 1, 2019 10:30 AM-12:45 PM
Optimizing PD-1/PD-L1 Immune Checkpoint Inhibitor Therapy: Dedicated to the Memory of Waun Ki Hong
Discussant
Stephen B Baylin
Johns Hopkins Univ. School of Medicine, Baltimore, MD, United States
from AACR Annual Meeting 2019 on April 1, 2019 10:30 AM-12:45 PM
Optimizing PD-1/PD-L1 Immune Checkpoint Inhibitor Therapy: Dedicated to the Memory of Waun Ki Hong
Tumor mutational burden (TMB) as a biomarker of survival in metastatic non-small cell lung cancer (mNSCLC): Blood and tissue TMB analysis from MYSTIC, a Phase III study of first-line durvalumab ± tremelimumab vs chemotherapy
Solange Peters
Centre Hospitalier Universitaire Vaudois, Lausanne University, Lausanne, Switzerland
from AACR Annual Meeting 2019 on April 1, 2019 10:30 AM-12:45 PM
Optimizing PD-1/PD-L1 Immune Checkpoint Inhibitor Therapy: Dedicated to the Memory of Waun Ki Hong
Discussant
David R Gandara
UC Davis Comprehensive Cancer Ctr., Sacramento, CA, United States
from AACR Annual Meeting 2019 on April 1, 2019 10:30 AM-12:45 PM
Optimizing PD-1/PD-L1 Immune Checkpoint Inhibitor Therapy: Dedicated to the Memory of Waun Ki Hong
Phase I evaluation of M7824, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus (HPV)-associated malignancies
Julius Strauss
Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States
from AACR Annual Meeting 2019 on April 1, 2019 10:30 AM-12:45 PM
Optimizing PD-1/PD-L1 Immune Checkpoint Inhibitor Therapy: Dedicated to the Memory of Waun Ki Hong
Discussant
Maura L Gillison
UT MD Anderson Cancer Ctr., Houston, TX, United States
from AACR Annual Meeting 2019 on April 1, 2019 10:30 AM-12:45 PM
Optimizing PD-1/PD-L1 Immune Checkpoint Inhibitor Therapy: Dedicated to the Memory of Waun Ki Hong
Pembrolizumab after two or more lines of prior therapy in patients with advanced small-cell lung cancer (SCLC): Results from the KEYNOTE-028 and KEYNOTE-158 studies
Hyun Cheol Chung
Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea, Republic of
from AACR Annual Meeting 2019 on April 1, 2019 10:30 AM-12:45 PM
Optimizing PD-1/PD-L1 Immune Checkpoint Inhibitor Therapy: Dedicated to the Memory of Waun Ki Hong
Discussant
Taofeek Kunle Owonikoko
Emory University, Atlanta, GA, United States
from AACR Annual Meeting 2019 on April 1, 2019 10:30 AM-12:45 PM
Biomarker Studies: Study Design and Statistical Considerations
From discovery to clinics: Design considerations in biomarker studies
Yingye Zheng
Fred Hutchinson Cancer Research Ctr., Seattle, WA, United States
from AACR Annual Meeting 2019 on March 29, 2019 5:15 PM-7:15 PM
Biomarker Studies: Study Design and Statistical Considerations
Needle in a haystack: Biomarker discovery in high-dimensional data
Shilin Zhao
Vanderbilt University Medical Center, Nashville, TN, United States
from AACR Annual Meeting 2019 on March 29, 2019 5:15 PM-7:15 PM
Biomarker Studies: Study Design and Statistical Considerations
Precision oncology: Integrating biomarkers in phase III clinical trial designs
Antje Hoering
Cancer Research and Biostatistics, Seattle, WA, United States
from AACR Annual Meeting 2019 on March 29, 2019 5:15 PM-7:15 PM
Biomarker Studies: Study Design and Statistical Considerations
Population risk stratification: Integrating biomarkers in cancer risk assessment
Ruth Pfeiffer
NCI-DCEG, Bethesda, MD, United States
from AACR Annual Meeting 2019 on March 29, 2019 5:15 PM-7:15 PM
Intersection of Radiation and Immune Therapy
Clinical experience with radiotherapy in the context of immune checkpoint blockade
Michael A. Postow
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from AACR Annual Meeting 2019 on March 29, 2019 5:15 PM-7:15 PM
Intersection of Radiation and Immune Therapy
Effects of radiation on tumor antigenicity and adjuvanticity: From mouse to human
Sandra Demaria
Weill Cornell Medical College, New York, NY, United States
from AACR Annual Meeting 2019 on March 29, 2019 5:15 PM-7:15 PM
<< first | < prev page: of 40 records per page: next > | last >>
pages: 1 2 3 4 5 ... 37 38 39 40 presentations: 1 to 25 of 990